Trend Tide News

NervGen Approaches Clinical Proof Of Concept Readout For Spinal Cord Regeneration (NGENF)


NervGen Approaches Clinical Proof Of Concept Readout For Spinal Cord Regeneration (NGENF)

Analyst's Disclosure: I/we have a beneficial long position in the shares of NGENF either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I am receiving compensation for this article but I have no business relationship with NervGen, and neither does the party that is compensating me. My bias, however, I would mainly attribute to my long position.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Previous articleNext article

POPULAR CATEGORY

commerce

10461

tech

10597

amusement

12713

science

5821

various

13510

healthcare

10317

sports

13529